139 related articles for article (PubMed ID: 24814603)
1. Danish guidelines for lipid-lowering treatment in patients with chronic renal failure.
Dieperink H; Christensen JH; Feldt-Rasmussen B; Schmidt EB; ;
Dan Med J; 2014 Apr; 61(4):C4843. PubMed ID: 24814603
[TBL] [Abstract][Full Text] [Related]
2. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
3. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.
Wanner C; Tonelli M;
Kidney Int; 2014 Jun; 85(6):1303-9. PubMed ID: 24552851
[TBL] [Abstract][Full Text] [Related]
4. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
7. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
[TBL] [Abstract][Full Text] [Related]
8. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
Marrs JC
Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
[TBL] [Abstract][Full Text] [Related]
9. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
10. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.
Heine GH; Rogacev KS; Weingärtner O; Marsche G
Semin Dial; 2017 Sep; 30(5):390-394. PubMed ID: 28628255
[TBL] [Abstract][Full Text] [Related]
11. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
Kanbay M; Turgut F; Covic A; Goldsmith D
J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
[TBL] [Abstract][Full Text] [Related]
13. Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines.
Shimizu R; Torii H; Yasuda D; Hiraoka Y; Kitada N; Hashida T; Yoshimoto A; Kita T; Kume N
J Atheroscler Thromb; 2015; 22(9):949-57. PubMed ID: 25843151
[TBL] [Abstract][Full Text] [Related]
14. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.
Nitta K
Clin Exp Nephrol; 2012 Aug; 16(4):522-9. PubMed ID: 22722878
[TBL] [Abstract][Full Text] [Related]
15. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
Suzuki H; Watanabe Y; Kumagai H; Shuto H
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):306-15. PubMed ID: 24280596
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia treatment and cardiovascular disease in the renal patient.
Burst V; Benzing T
Curr Pharm Des; 2011; 17(9):894-907. PubMed ID: 21418028
[TBL] [Abstract][Full Text] [Related]
19. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
Molitch ME
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
[TBL] [Abstract][Full Text] [Related]
20. [Diminished glomerular filtration rate as a marker of chronic kidney disease in hypertensive patients].
Grabysa R; Cholewa M
Pol Merkur Lekarski; 2008 Jun; 24(144):487-91. PubMed ID: 18702327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
